| Outcome Measures: |
Primary: Changes of cognitive function assessed by cognitive function scale after 12 weeks., The cognitive function will be calculated from performance on the following measures: (1)Digit Span Test(DST);(2) Rey Auditory Verbal Learning(RAVL);(3) Long-Delay Free Recall(LDFR);(4) Trail Making Test(TMT);(5) Animal Naming Test(ANT);(6) Clock Drawing Test(CDT);(7)Minimum Mental State Examination(MMSE);(8)Memory and executive screening(MES);(8)functional near-infrared spectroscopy., Baseline,4weeks,8weeks，12weeks(End of Trial) | Secondary: Changes of systolic blood pressure and diastolic blood pressure, Change of systolic blood pressure and diastolic blood pressure compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of fasting plasma glucose, Change of fasting plasma glucose compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of HbA1c, Change of HbA1c compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of lipid profile, Change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of liver enzymes, Change of liver enzymes (ALT, AST in IU/L) compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of kidney function, Change of kidney function（serum creatinine in umol/L、eGFR in ml/min） compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of CRP, Change of CRP compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of Body mass index(BMI), Change of Body mass index(BMI) compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of waist circumference, Change of waist circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of hip circumference, Change of hip circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)|Change of waist-to-hip ratio, Change of waist-to-hip ratio compared with baseline, and between the intervention and control group at the end of the study (12 weeks), Baseline,4weeks,8weeks，12weeks(End of Trial)
|
